ACTIVITIES OF 2 NEW TEICOPLANIN AMIDE DERIVATIVES (MDL-62211 AND MDL-62873) COMPARED WITH ACTIVITIES OF TEICOPLANIN AND VANCOMYCIN AGAINST 800 RECENT STAPHYLOCOCCAL ISOLATES FROM FRANCE AND THE UNITED-STATES

MDL 62211 is the amide derivative of the teicoplanin complex and MDL 62873 is a more focused amide derivative of the teicoplanin A2-2 peak. Each investigational compound had nearly identical activity and was 2- to 16-fold more active than teicoplanin or vancomycin. The MDL 62873 MICs for 90% of the strains tested were as follows: Staphylococcus aureus, oxacillin susceptible, 0.12-mu-g/ml; S. aureus, oxacillin resistant, 0.25-mu-g/ml; coagulase-negative staphylococci (CNS), oxacillin susceptible, 0.25-mu-g/ml; and CNS, oxacillin resistant, 2-mu-g/ml. CNS isolates from France were generally more susceptible than those tested in the United States. Teicoplanin-resistant U.S. isolates were usually Staphylococcus haemolyticus (1.8% of all tested strains), for which MICs ranged from 32 to > 128-mu-g/ml. MDL 62873 was not active against the Bacteroides fragilis group but was generally effective against gram-positive anaerobic strains.